West Dedicates Pharmaceutical Manufacturing Plant in India
West Pharmaceutical Services, Inc. has dedicated its manufacturing plant in the Sri City Special Economic Zone (SEZ), where the company will expand its growing primary packaging for injectable medicines business.
"West is experiencing a very exciting period of growth and business expansion in Asia and we are proud to open our first facility in India," said Donald E. Morel, Jr, West's Chairman and Chief Executive Officer. "With more and more pharmaceutical customers establishing operations in India, our new plant will help West meet market demand and further establishes the company's presence in this growing and dynamic market.
"On behalf of West's Board of Directors, I would like to thank the many representatives of the Indian government for their support throughout the planning process. This new facility in Sri City will allow West to continue to satisfy the needs of our customers, who are serving a growing number of patients in India and the Asia Pacific region."
In June 2012, West signed a 99-year lease on 72,800 m2 of land in Sri City. Sri City offers the advantages of a metropolitan location and was selected primarily on the suitability of land, availability of utilities, labour suitability, logistics and quality of life.
Construction began in August 2012 on a 15,300 m2 facility that will produce seals used in primary packaging of injectable medicines manufactured by West's pharmaceutical and biopharmaceutical customers in India and the wider Asia Pacific region. There are future plans to expand production at the site to include West's elastomer component business.
"This investment is important to our strategy of partnering with customers in India and the Asia Pacific region to help them provide medicines to patients more efficiently, reliably and safely," said Warwick Bedwell, President, Pharmaceutical Packaging Systems, Asia Pacific Region. "With the facility complete, we anticipate a reduction in lead times for supply to our customers in India. By leveraging our global sourcing activities and process engineering expertise, we expect to be able to carefully manage the overall costs of production."
West's presence in the Asia Pacific market includes a plant in Singapore, two plants in Qingpu, China and sales offices in Australia, China, India and Singapore. West also owns 25% of Daikyo Seiko, Ltd, Tokyo, Japan. Daikyo Seiko, founded in 1954, is a leader in the fields of pharmaceutical packaging and medical device components. The West/Daikyo relationship was formed in 1973 and includes joint marketing agreements and technology transfer and licensing agreements.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance